{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:25Z","timestamp":1793047045425,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40291-026-00882-1","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:38:04Z","timestamp":1789637884000},"page":"1003-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Orca-T: First Approval"],"prefix":"10.1007","volume":"30","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189676","author":"M Hefazi","year":"2021","unstructured":"Hefazi M, Bolivar-Wagers S, Blazar BR. Regulatory T cell therapy of graft-versus-host disease: advances and challenges. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22189676.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"882_CR2","first-page":"1","volume":"1","author":"J Heinrichs","year":"2016","unstructured":"Heinrichs J, Bastian D, Veerapathran A, et al. Regulatory T-cell therapy for graft-versus-host disease. J Immunol Res Ther. 2016;1(1):1\u201314.","journal-title":"J Immunol Res Ther."},{"issue":"7","key":"882_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41409-025-02553-x","volume":"60","author":"M Lysandrou","year":"2025","unstructured":"Lysandrou M, Kefala D, Vinnakota JM, et al. Regulatory T cell therapy for graft-versus-host disease. Bone Marrow Transplant. 2025;60(7):933\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"882_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.16157","volume":"187","author":"S Elias","year":"2019","unstructured":"Elias S, Rudensky AY. Therapeutic use of regulatory T cells for graft-versus-host disease. Br J Haematol. 2019;187(1):25\u201338.","journal-title":"Br J Haematol"},{"key":"882_CR5","unstructured":"U.S. Food & Drug Administration. FDA approves new treatment that uses donor immune cells to prevent serious complications in blood cancer patients [media release]. 30 June 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-uses-donor-immune-cells-prevent-serious-complications-blood-cancer."},{"key":"882_CR6","unstructured":"Orca Bio. Orca Bio receives Regenerative Medicine Advanced Therapy (RMAT) designation for Orca-T [media release]. 14 Oct 2020. http:\/\/www.orcabio.com."},{"key":"882_CR7","unstructured":"Orca Bio. Orca Bio announces FDA acceptance and priority review of the Biologics License Application (BLA) for Orca-T\u00ae to treat hematological malignancies [media release]. 6 Oct 2025. http:\/\/www.orcabio.com."},{"key":"882_CR8","unstructured":"Orca Biosystems Inc. TREGZITM (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) suspension, for intravenous infusion: US prescribing information. 2026. https:\/\/orcabio.com\/wp-content\/uploads\/2026\/07\/TREGZI-USPI-June-2026.pdf. Accessed 7 Sept 2026."},{"key":"882_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00163","volume":"4","author":"AJ Beres","year":"2013","unstructured":"Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013;4:163.","journal-title":"Front Immunol"},{"issue":"2","key":"882_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood-2007-07-103895","volume":"111","author":"VH Nguyen","year":"2008","unstructured":"Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111(2):945\u201353.","journal-title":"Blood"},{"issue":"2","key":"882_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbmt.2019.10.026","volume":"26","author":"X Gao","year":"2020","unstructured":"Gao X, Xu C, Li B, et al. Quantitative analysis of thymus-independent donor-derived T cell expansion in transplant patients. Biol Blood Marrow Transplant. 2020;26(2):242\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"882_CR12","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.1182\/blood-2011-02-334623","volume":"117","author":"W Krenger","year":"2011","unstructured":"Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768\u201376.","journal-title":"Blood"},{"key":"882_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01237","volume":"9","author":"MM Moutuou","year":"2018","unstructured":"Moutuou MM, Page G, Zaid I, et al. Restoring T cell homeostasis after allogeneic stem cell transplantation; principal limitations and future challenges. Front Immunol. 2018;9:1237.","journal-title":"Front Immunol"},{"issue":"5","key":"882_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","volume":"19","author":"KM Williams","year":"2007","unstructured":"Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol. 2007;19(5):318\u201330.","journal-title":"Semin Immunol"},{"issue":"11","key":"882_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood.2025031313","volume":"147","author":"EH Meyer","year":"2026","unstructured":"Meyer EH, Salhotra A, Gandhi AP, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026;147(11):1168\u201377.","journal-title":"Blood"},{"issue":"5","key":"882_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/bloodadvances.2023011625","volume":"8","author":"CS Bader","year":"2024","unstructured":"Bader CS, Pavlova A, Lowsky R, et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Adv. 2024;8(5):1105\u201315.","journal-title":"Blood Adv"},{"issue":"18","key":"882_CR17","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/blood.2024026446","volume":"145","author":"EH Meyer","year":"2025","unstructured":"Meyer EH, Pavlova A, Villar-Prados A, et al. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025;145(18):2012\u201324.","journal-title":"Blood"},{"key":"882_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.08.037","author":"CH Oliai","year":"2026","unstructured":"Oliai CH, Gandhi A, Hoeg RT, et al. Observational comparison of overall survival between phase 1b Orca-T and registry-based post-transplant cyclophosphamide patients. Transplant Cell Ther. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.08.037.","journal-title":"Transplant Cell Ther."},{"issue":"2 Suppl","key":"882_CR19","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1016\/j.jtct.2025.12.188","volume":"32","author":"A Salhotra","year":"2026","unstructured":"Salhotra A, Dandapani S, Yang DY, et al. Single center phase 1b study of Orca-T following escalated doses of total marrow and lymphoid irradiation (TMLI) in patients with acute leukemia or MDS [abstract no. 172]. Transplant Cell Ther. 2026;32(2 Suppl):S140.","journal-title":"Transplant Cell Ther."},{"issue":"2 Suppl","key":"882_CR20","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jtct.2025.12.047","volume":"32","author":"A Molina","year":"2026","unstructured":"Molina A, Shiraz P, Kanegai A, et al. Mature outcomes from the phase I trial of Orca-T and allogeneic CD19\/CD22 CAR-T cells for adults with high-risk B-ALL [abstract no. 31]. Transplant Cell Ther. 2026;32(2 Suppl):S27.","journal-title":"Transplant Cell Ther."},{"issue":"Suppl 1","key":"882_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2025-111","volume":"146","author":"A Villar-Prados","year":"2025","unstructured":"Villar-Prados A, Kim P, Sutherland K, et al. Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: results of a single center phase 1 study [abstract]. Blood. 2025;146(Suppl 1):111\u20132.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00882-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:04:10Z","timestamp":1793045050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00882-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00882-1","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}